News & Blog

News & Blog

  • Reset
News | Aug 14 2023

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels i...

Industry News
News | Aug 11 2023

2023 FARA Fellows

The FARA Fellow Program recognizes young investigators who will commit their early career to FA research and want to grow their profile ...

FARA News | Research
News | Jul 25 2023

Larimar Therapeutics Receives FDA Clearance

Industry News
News | Jul 25 2023

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich’s Ataxia Trial and to Initiate Open Label Extension Trial

Industry News
News | Jun 13 2023

Lexeo Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy

Industry News
News | Jun 5 2023

FARA Celebrates the 15th Annual Ataxian Athlete Initiative (AAI) for People with Ataxia

News | May 30 2023

May 2023 – Advocacy Newsletters

Advocacy
News | May 23 2023

PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial

Industry News
News | May 15 2023

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort – First Quarter 2023 Financial Results

Industry News
News | May 15 2023

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohor

Industry News
News | May 15 2023

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results

Industry News
News | Apr 30 2023

April 2023 – Advocacy Newsletter

Advocacy